Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Pfizer CEO is set to meet with activist investor Starboard Value after the investor acquired a $1 billion stake in the ...

Albert Bourla could be seen saying: "We know that the two doses of the vaccine offer very limited protection, if any." Jerome tweeted: "If this video is legit, it has to sound off some alarms ...

DAVOS, Switzerland—Albert Bourla ... two weight-loss pills that could have been a game-changing opportunity. “We will continue and I’m sure that successes will come,” Bourla says.

Pfizer’s chief executive, Dr. Albert Bourla, said the drug-making company is in a “very advanced stage” and should know by the end of October whether the coronavirus vaccine they are ...

Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...

“Albert Bourla is very proud of his Greek heritage and of his Jewish heritage, from Thessaloniki,” the Israeli prime minister said. (JTA) — Israel’s government has signed an agreement with ...

Since Albert Bourla settled into the captain’s chair ... show that Big Pharma stocks are more like trading vehicles than blue ...

There have been a lot of different mass storage methods over the relatively short lifespan of the computer. Magnetic tapes, drums, all sorts of disks, and flash memory have each had their time ...

A chip packaging technique in which the active area of the chip is "flipped over" facing downward. Instead of facing up and bonded to the package leads with wires from the outside edges of the ...

Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing Albert Bourla talks about his employees' effort to develop a COVID-19 vaccine in record ...

Albert Bourla said Pfizer expects to price its treatment, called Paxlovid, close to where rival Merck & Co Inc has priced its oral antiviral drug candidate. The companies said the vaccine ...